NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart conditionNICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has Share XNICE says ‘no’ to Pfizer’s Vyndaqel for rare heart conditionhttps://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/
Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe, Share XPfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/
